by | Mar 14, 2019 | net updates
NET CONNECT has summarised highlights from the recent ENETS 2019 meeting for you. Clinical impact of the WHO classification 2017 by Dr. Elettra Merola, Santa Chiara Hospital (APSS), Italy Download the slides Bio-markers in NENs by Dr. Kira Oleinikov, Hadassah-Hebrew...This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
This website is intended for healthcare professionals only. Please let us share with you the background to such educational programmes provided by COR2ED, a leading provider of high quality independent medical education.
The material and content contained in this website are for healthcare professionals only.
Dr. Emily Bergsland is a Professor of Medicine and the Ernest Rosenbaum, MD, Endowed Chair in Medical Oncology at the University of California-San Francisco (UCSF). She has spent twenty years developing a clinical and research program focused on neuroendocrine tumours. Her clinical and research efforts are focused on advancing the care of patients with neuroendocrine neoplasms (NENs), understanding why NENs develop, and the development and testing of novel, biologically based therapies for NENs.
Dr. Bergsland is the Director of the University of California-San Francisco (UCSF) Centre for Neuroendocrine Tumours, Chair of the UCSF GI Oncology Site Committee and an active member of the Phase I Site Committee. Nationally, she is Chair of the Neuroendocrine Tumour Task Force of the National Cancer Institute (NCI) Gastrointestinal (GI) Steering Committee, a member of the NCCN Neuroendocrine Tumours Guidelines Panel, and is the current Vice-Chair (Chair-elect) of the North American Neuroendocrine Tumour Society (NANETS). She was also study chair for ALLIANCE A021202 (a randomized phase II trial of pazopanib v placebo in patients with progressive carcinoid tumours), a completed study which included a prospective plan for central review and archiving of serial radiologic images and blood sample collection for angiome profiling (analyses are pending).
Recent Comments